Suven Life Sciences has been granted patent by Australia, China, Europe, South Korea and the US for a drug used in the treatment of neuro-degenerative diseases.
The patents are valid until 2031, 2030, 2031, 2030 and 2031, respectively, Suven Life Sciences said in a BSE filing.
Suven Life CEO Venkat Jasti said: “We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally.”
The company has “secured patents in Australia, China, Europe, South Korea and USA to their new chemical entities for CNS therapy through mechanism of action — H3 Inverse against’’.
With these new patents, Suven has 22 granted patents from Australia, 19 from China, 17 from Europe, 17 from South Korea and 23 from the US.
“These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts.
“Products out of these inventions may be out-licensed at various phases of clinical development like at Phase-I or Phase-II,” Suven said.